ARWR — Arrowhead Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00
- $2.67bn
- $2.24bn
- $240.74m
2019 September 30th | 2020 September 30th | 2021 September 30th | 2022 September 30th | 2023 September 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 169 | 88 | 138 | 243 | 241 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Total Operating Expenses | 108 | 181 | 287 | 422 | 446 |
Operating Profit | 61.2 | -93.2 | -149 | -179 | -205 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 68.1 | -84.6 | -141 | -173 | -206 |
Provision for Income Taxes | |||||
Net Income After Taxes | 68 | -84.6 | -141 | -176 | -209 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 68 | -84.6 | -141 | -176 | -205 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 68 | -84.6 | -141 | -176 | -205 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.689 | -0.839 | -1.36 | -1.67 | -1.92 |